Navigation Links
BioBDx to Present at the 2011 BioPharm America Conference
Date:8/31/2011

PLYMOUTH MEETING, Pa., Aug. 31, 2011 /PRNewswire/ -- BioBDx announced today that the Company's Chairman and CEO Byron Hewett will present at the 2011 BioPharm America Conference taking place September 7-9.  BioBDx manufactures and markets the Quotient® System, a tool that objectively measures brain functions related to deficits in response inhibition. The first FDA-cleared application of this platform technology is objective measurement of hyperactivity, impulsivity and inattention as an aid in the assessment of attention-deficit hyperactivity disorder (ADHD).  Mr. Hewett will provide a company overview and update on the Quotient ADHD System on Thursday, September 8 at 4:15 p.m. EDT in the Otis room at the Westin Boston Waterfront Hotel in Boston, MA.

About the Quotient® ADHD TestThe Quotient® ADHD Test measures motion and analyzes shifts in attention state to give an objective picture of the core symptom areas of ADHD.  Clinicians use the Quotient® ADHD Test at the initial visit to assess severity of the three core symptoms of ADHD; hyperactivity, inattention and impulsivity.  Patients may be re-assessed periodically at follow-up visits to guide treatment plans.  The clinician integrates the Quotient® ADHD Test report with information from other assessment tools and the clinical evaluation to help guide the discussion on the treatment plan. For more information about the Quotient® ADHD System, please visit http://www.biobdx.com/products

About BioBehavioral Diagnostics CompanyBioBDx manufactures and markets the Quotient System, a tool that aids in the objective and accurate assessment of neural control functions related to deficits in inhibitory control.  We are dedicated to providing physicians, parents and patients with high-value information to guide personalized strategies and to enhance quality of life for patients with ADHD. &
'/>"/>

SOURCE BioBDx
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
4. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
5. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
8. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
9. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
10. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
11. ViroPharma to Present at Three Upcoming Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... and Tobago , July 25, 2014 /PRNewswire/ ... Trinidad & Tobago Ministry of Health approved the ... that significantly increases the cure rate from Hepatitis ... with the genotype 1 virus. Telaprevir is available ... trade brand INCIVO®. Photo - ...
(Date:7/25/2014)... July 25, 2014  Acsis Inc., the market ... serialization solutions, has recently posted an article, ... current and future needs for companies, extended supply ... supply chain model no longer work today.  The ... the growth of mobile technology, machine to machine ...
(Date:7/25/2014)... July 25, 2014 According to ... "Global and China Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, ... Share, Growth, Trends and Forecast (Value and Volume), 2013 ... USD 19.99 billion in 2012 and is expected to ... 2019 to reach USD 32.24 billion in 2019. ...
Breaking Medicine Technology:The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3Acsis Addresses Questions on the Modern Supply Chain 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4
... by March of Dimes Grantee Offers Hope for Treatment ... new gene-based,technique has successfully prevented a rare craniofacial birth ... the same disorder, according,to new research funded in part ... is being published in the journal Nature Medicine,demonstrates the ...
... /Xinhua-PRNewswire-FirstCall/ -- Lotus Pharmaceuticals,Inc. (OTC Bulletin Board: ... in the People,s Republic of China ("PRC"), ... in the development of,isosorbide mononitrate sustained release ... and treatment of angina., Based on ...
Cached Medicine Technology:Molecular Therapy Succeeds in Preventing Craniofacial Birth Defect in Mice 2Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets 2Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets 3
(Date:7/28/2014)... 28, 2014 According to the Drama Method ... relationship guide that helps women easily get the attention of ... Vkool reveals in its review that this book can teach ... their man. The book also instructs them how to conquer ... in its Drama Method review that this book is divided ...
(Date:7/28/2014)... Dr. Alan Xenakis, MD announced today the release of ... new book, DOC X MD Funny Feelings translates ... style with humor and medical accuracy. The book is creatively ... answers to those age-old questions that most folks are embarrassed ... do mosquitoes bite some and not others? Why do folks ...
(Date:7/27/2014)... Recently, Wdsshop.de, a reliable online supplier of women’s ... prom dresses on its website. Now, all these ... 58% off. , “We are pleased to add the new ... specially created for those who are in need of fashionable ... in style. I think our clients will love them. Ladies, ...
(Date:7/27/2014)... shown that a powerful drug given at the time ... early risk of rejection, but that it also allows ... used after the operation. , The key results are ... the World Transplant Congress in San Francisco today. They ... the powerful combinations of treatments used to prevent early ...
(Date:7/27/2014)... why medication to treat asthma and pneumonia can become ineffective. ... that drugs widely used to treat lung diseases work with ... which is caused by an infection, affects around 1 in ... young children, the elderly, smokers and those with an underlying ... the UK are affected by asthma and the NHS spends ...
Breaking Medicine News(10 mins):Health News:The Drama Method Pdf Review Exposes Aaron Fox's Relationship Guide – Vkool.com 2Health News:The Drama Method Pdf Review Exposes Aaron Fox's Relationship Guide – Vkool.com 3Health News:New Book by Alan P. Xenakis, MD Reveals Mind and Body Mysteries 2Health News:Wdsshop.de Unveils New Prom Dresses To Expand The Online Market 2Health News:Kidney transplant drug halves the early risk of rejection and allows less toxic treatment 2Health News:Kidney transplant drug halves the early risk of rejection and allows less toxic treatment 3Health News:Drugs used to treat lung disease work with the body clock 2
... this Valentine,s Day and give the friends and family ... gift that will satisfy,their sweet tooth, warm their heart ... new Organic Chocolate Single Serve is a deep chocolate,nectar ... all of the,fat, cholesterol and calories," said Pam Dietz, ...
... A new company has joined the fight against MRSA ... have launched a new company, Inspiralis Ltd, based around ... enzymes that help DNA molecules to unravel and wind ... , DNA becomes tangled as a result of ...
... Nearly 90,000 Annual ... ... provider of,point-of-care charge capture technologies, today announced that its,customer, the ... Infusion Services Module., The Module, an extension of MedAptus, ...
... of Men With Erectile Dysfunction Are Smokers, NEW ... image and attractiveness, it does the exact opposite when ... According to recent studies, 60-percent of all men who ... partners burning,for more passion. In an effort to dramatically ...
... of the Cancion(R) System in Patients ... Hospitalized with Heart Failure, ... products company developing and marketing devices to,treat heart failure, announced ... Breaking Clinical Trial presentation at the,upcoming annual American College of ...
... Noyes announced today that,the firm represented The Riverside Company ... to Halyard Capital. The management team will,continue to have ... transaction,were not disclosed., "This is an excellent match ... winning healthcare and information franchise," said,Tom O,Connor, the Berkery ...
Cached Medicine News:Health News:Give Vitasoy's 'Liquid Love' for Heart Month! 2Health News:DNA with a twist: New company to search for cancer drugs and antibiotics 2Health News:Dana-Farber Cancer Institute Completes Deployment of MedAptus' Infusion Services Module 2Health News:Dana-Farber Cancer Institute Completes Deployment of MedAptus' Infusion Services Module 3Health News:The Best Way to Stoke Your Valentine's Fire: Don't Light Up 2Health News:Orqis(R) Medical's MOMENTUM Trial Abstract Accepted for Late Breaking Clinical Trial Presentation at the American College of Cardiology Annual Meeting 2Health News:Berkery Noyes Represented The Riverside Company on the Sale of HCPro Holdings, Inc. to Halyard Capital, LLC 2Health News:Berkery Noyes Represented The Riverside Company on the Sale of HCPro Holdings, Inc. to Halyard Capital, LLC 3
... incubators hold rotators and agitators ... can be set at 22C ... to 40C (59F to 104F). ... top to bottom. Recorder is ...
... Platelet incubators hold rotators and ... temperature can be set at ... 15C to 40C (59F to ... from top to bottom. Recorder ...
This model of bench top refrigerated incubator has been designed to suit the TPS-32 platelet shaker....
An enzyme-linked immuno-sorbent assay for the detection and quantitation of anti-tissue Transglutaminase in serum of patients with Celiac Disease and Dermatitis Herpetiformis....
Medicine Products: